February 6, 2019

No deal brexit’s impact on the pharmaceutical and medical devices industries: guidance from the ema and the european commission

On January 15, 2019, the UK House of Commons rejected the withdrawal agreement reached by Theresa May and the EU after a long and exhausting negotiation period of almost 2 years. On March 29, 2019, the UK will officially leave the EU unless Article 50 of the Treaty on European Union is delayed or revoked. A delay in the UK leaving the EU seems to be the most reasonable and conservative option at this stage, but the future is profoundly uncertain and a No Deal Brexit is becoming an increasingly more realistic possibility by the day.

In relation to the above, the European Medicines Agency and the European Commission are providing guidance on Brexit for pharmaceutical companies, including launching a dedicated page on their website.

On February 1, 2019, the European Commission published an updated Q&A document on the topic of the UK’s withdrawal from the EU with regard to industrial products, including medical devices, and medical products for human and veterinary use, which can be viewed at the following links:

–          Medical products for human and veterinary use

–          Industrial products, including medical devices

These FAQs address the scenario in which the UK will leave the EU without any transition period or without any other arrangements being put in place, and therefore having a potentially disruptive impact on businesses. In this case, the UK will immediately become a third country from the EU’s perspective.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide newsinsights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
June 6, 2022
The National Coordination Centre for Ethics Committees published new draft agreements for conducting clinical trials on drugs and medical devices
April 27, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on the borderline between medical devices and medicinal products in order to support the uniform application of Regulation...
April 5, 2022
Electronic prescriptions: the current modalities of transmission from doctors to patients and from patients to pharmacies are extended until 31st December 2022
March 24, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on appropriate surveillance of devices covered by certificates according to the MD Directives, under the transitional prov...
March 21, 2022
Published Decree of Health Ministry identifying the ethics committees of national significance for clinical trials of medicinal products and medical devices
Search by...
Search
Follow us on
Follow us on